Strokes and their relationship to hypertension

被引:23
作者
Dickinson, CJ [1 ]
机构
[1] Univ London, Queen Mary, Wolfson Inst Prevent Med, London EC1M 6BQ, England
关键词
haemorrhagic transformation; ischaemic stroke pathology; plasminogen activator therapy; statin prophylaxis;
D O I
10.1097/00041552-200301000-00015
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review There is rapidly growing appreciation that stroke morbidity and the risk of an ischaemic stroke becoming haemorrhagic can be influenced by new information about prophylaxis, rapid diagnosis and treatment. Recent findings Strokes are strongly associated with hypertension mainly because hypertension is strongly associated with atheromatous deposits blocking or narrowing brain arteries, predisposing to local clot formation. Atheroma and its ischaemic consequences may damage cerebral arterioles and the brain tissue they supply. Cerebral infarcts are more common than spontaneous cerebral haemorrhages. High blood pressure itself cannot directly rupture cerebral blood vessels because their small size protects them and intracerebral haemorrhage usually follows previous ischaemic vascular damage. It is obvious that lowering blood pressure would reduce the risk and extent of bleeding into the brain once a break in an arteriolar wall has occurred, but it is not clear why lowering blood pressure should protect against cerebral infarction. One might expect that slowing down the rate of cerebral blood flow would give more time for local clots to form. It seems most likely that induced hypotension protects against ischaemic strokes by preventing pressure- or ischaemia-induced arteriolar spasm and by advantageous vasodilation of some of the more ischaemic territories. Added protection can be provided by coenzyme-A reductase inhibitors (statins), but probably not by antioxidants. Summary Lowering blood pressure strongly protects against ischaemic and haemorrhagic stroke. Recent work shows that more accurate and faster diagnosis of stroke pathology is urgently needed, so that appropriate treatment (e.g. with tissue plasminogen activators) can be started before local bleeding has occurred.
引用
收藏
页码:91 / 96
页数:6
相关论文
共 79 条
[1]   Emergent use of anticoagulation for treatment of patients with ischemic stroke [J].
Adams, HP .
STROKE, 2002, 33 (03) :856-861
[2]   ATLANTIS trial - Results for patients treated within 3 hours of stroke onset [J].
Albers, GW ;
Clark, WM ;
Madden, KP ;
Hamilton, SA .
STROKE, 2002, 33 (02) :493-495
[3]   High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial Doppler monitoring [J].
Alexandrov, AV ;
Demchuk, AM ;
Felberg, RA ;
Christou, I ;
Barber, PA ;
Burgin, WS ;
Malkoff, M ;
Wojner, AW ;
Grotta, JC .
STROKE, 2000, 31 (03) :610-614
[4]   Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke [J].
Arenillas, JF ;
Rovira, A ;
Molina, CA ;
Grive, E ;
Montaner, J ;
Sabin, JA .
STROKE, 2002, 33 (09) :2197-2203
[5]   HYPERTENSION AND CEREBRAL ATHEROSCLEROSIS [J].
BAKER, AB ;
RESCH, JA ;
LOEWENSON, RB .
CIRCULATION, 1969, 39 (05) :701-+
[6]   Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility [J].
Barber, PA ;
Zhang, J ;
Demchuk, AM ;
Hill, MD ;
Buchan, AM .
NEUROLOGY, 2001, 56 (08) :1015-1020
[7]  
BELICHENKO OL, 1994, VISTNIK RENTGENOL RA, V3, P25
[8]  
BONDJERS G, 1991, CIRCULATION, V84, P2
[9]   γ-Glutamyltransferase and risk of stroke:: the EUROSTROKE project [J].
Bots, ML ;
Salonen, JT ;
Elwood, PC ;
Nikitin, Y ;
de Concalves, AF ;
Inzitari, D ;
Sivenius, J ;
Trichopoulou, A ;
Tuomilehto, J ;
Koudstaal, PJ ;
Grobbee, DE .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2002, 56 :I25-I29
[10]   Hypertension in the Very Elderly Trial (HYVET) - Protocol for the Main Trial [J].
Bulpitt, C ;
Fletcher, A ;
Beckett, N ;
Coope, J ;
Gil-Extremera, B ;
Forette, F ;
Nachev, C ;
Potter, J ;
Sever, P ;
Staessen, J ;
Swift, C ;
Tuomilehto, J .
DRUGS & AGING, 2001, 18 (03) :151-164